Table: Sumitomo Pharma -9-MTH group results (IFRS)

Sumitomo Pharma

31/01/2023 06:30

Jan 31 (Reuters)- 
              Sumitomo Pharma Co., Ltd. 
              CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified) 
                 9 months ended      9 months ended        Year to  
                Dec 31, 2022        Dec 31, 2021      Mar 31, 2023  
                   LATEST             YEAR-AGO           COMPANY    
                   RESULTS             RESULT           FORECAST    
  Sales            460.27              432.07            563.00     
                 (+6.5 pct)          (+9.5 pct)        (+0.5 pct)   
  Operating      loss 17.78             58.23          loss 27.00   
                                     (-33.5 pct)                    
  Pretax
  Net            loss 18.50             46.36          loss 35.00   
                                     (-34.0 pct)                    
  EPS Basic    loss 46.57 yen        116.69 yen      loss 88.10 yen 
  Ann Div                             28.00 yen         28.00 yen   
  -Q2 Div         14.00 yen           14.00 yen                     
  -Q4 Div                             14.00 yen         14.00 yen   
 
  NOTE - Sumitomo Pharma Co., Ltd.. 
  (Figures are reported based on international accounting rules (IFRS).) 
  If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half 
  dividend and Q4 to the second-half dividend announced before a new corporate law in 
  2006 allowed companies to pay and report dividends on a quarterly basis.
  *Net - represents Net profit attributable to owners of the parent company. 
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4506.T